Fig. 3
From: Secreting-lux/pT-ClyA engineered bacteria suppresses tumor growth via interleukin-1β in two pathways
Effect of engineered lux/pT-ClyA-expressing Salmonella on growth and survival of CT26 tumors. BALB/c mice (n = 6 per group) were surgically implanted with one piece of CT26 tumor in the ceca colon. When tumors reached a volume of approximately 120–180 mm3, mice were divided into five treatment groups. Groups received intravenous (i.v.) injections of PBS, ΔppGpp S. typhimurium, or ΔppGpp S. typhimurium carrying lux/pT-ClyA either with (+) or without (−) doxycycline induction. For IL-1β depletion, mice received an i.v. injection of anti-IL-1β-specific antibody (IL-1β Ab) 1 day before engineered Salmonella typhimurium secreting lux/pT-ClyA (Day 1). The antibody was then injected twice a week for 2 weeks. Where relevant, mice received 17 mg/kg/day doxycycline. a Images of tumors from representative mice from each group. b Changes in tumor size. c Kaplan–Meier survival curves for CT26 tumor-bearing mice. Statistical significance was calculated by comparison with PBS or S.t-ΔpG lux/pT-ClyA(+)+IL-1βAb